Biota Holdings

What Biota Holdings does

Vaxart Inc. is a clinical-stage biotechnology company developing oral recombinant pill vaccines based on its proprietary VAAST Platform. The company's core technology is an oral vaccine delivery architecture designed to generate both durable mucosal immunity at the point of viral entry and systemic immunity throughout the body, eliminating the need for needles, cold-chain storage, and healthcare-professional administration. Its pipeline spans four indications — COVID-19 (currently in Phase 2b with a 400-participant Sentinel Safety Cohort reporting 12-month safety data), norovirus, influenza, and HPV — all leveraging the same VAAST oral delivery foundation.

Vaxart has no commercialized products, no published pricing, and no revenue. Its sole current distribution mechanism is regulated clinical trial programs, and it has signaled that future commercialization would rely on pharmaceutical distribution partnerships rather than owned channels. The company targets global populations in need of accessible, needle-free vaccination against common viral diseases, and frames its mission around global health accessibility rather than a narrow commercial segment. Customer-facing activity is limited to investor relations, press releases, and corporate social media (LinkedIn and X).

Note on input: the supplied data set is labeled "Biota Holdings," but every populated field describes Vaxart Inc., and the Biota Holdings records themselves contain no substantive information. This analysis is therefore written for Vaxart Inc. as the actual subject of the source data. Capital-markets signals in July 2026 include a stockholder cooperation agreement with board and governance enhancements and the annual meeting of stockholders, alongside the clinical readout — consistent with a pre-revenue biotech navigating governance pressure while advancing its pipeline.

Name

Biota Holdings

Website

https://biota.com.au

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

51–100 employees

Short description

Vaxart Inc. is a clinical-stage biotechnology company developing oral recombinant pill vaccines for COVID-19, norovirus, influenza, and HPV using its proprietary VAAST mucosal immunity platform, targeting global populations in need of needle-free, cold-chain-independent vaccination.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF)

Keywords

• Oral pill vaccines
• Recombinant vaccines
• Mucosal immunity
• Clinical-stage biotechnology
• Vaccine development

Headquarters

HQ city

Notting Hill

HQ country

Australia

HQ region

Oceania

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Distribution channels1 record

Marketing channels3 records

Core offering

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary VAAST (Vaxart's Adventitious Agent Screening Technology) delivery platform. The company's pipeline targets COVID-19, norovirus, influenza, and HPV using oral pill vaccines designed to generate both mucosal and systemic immunity, eliminating the need for needles or cold chain storage.

Product overview

Vaxart Inc. is a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary VAAST Platform. The company's portfolio consists of multiple vaccine candidates targeting COVID-19, norovirus, influenza, and HPV, all delivered as oral pills designed to generate both mucosal and systemic immunity. The VAAST Platform serves as the core technology underlying all pipeline products, with the COVID-19 vaccine candidate currently in Phase 2b trials and others in various development stages.

Differentiator

Problem solved

Functional benefit

Products and services

• VAAST Platform A proprietary oral vaccine delivery platform designed to generate durable mucosal and systemic immunity through recombinant pill vaccines, eliminating the need for needles or injections.
• Oral Pill COVID-19 Vaccine An oral pill vaccine candidate targeting COVID-19, currently in Phase 2b clinical trial with a 400-participant Sentinel Safety Cohort reporting topline 12-month safety data.
• Oral Pill Norovirus Vaccine An oral pill vaccine candidate targeting norovirus, part of the company's pipeline of mucosal vaccines leveraging the VAAST platform.
• Oral Pill Influenza Vaccine An oral pill vaccine candidate targeting influenza, leveraging the VAAST platform's mucosal immunity approach.
• Oral Pill HPV Vaccine An oral pill vaccine candidate targeting human papillomavirus (HPV), utilizing the company's oral delivery platform to generate mucosal and systemic immunity.

Quantifiable outcome

• Phase 2b clinical trial of oral pill COVID-19 vaccine with 400-participant Sentinel Safety Cohort reporting topline 12-month safety data.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• HilleVax: Clinical-stage biopharmaceutical company developing a vaccine for norovirus gastroenteritis. Highly comparable to Vaxart given similar indication (norovirus) and clinical-stage vaccine development profile.

Broad incumbents

• BioNTech: mRNA vaccine pioneer, co-developer of Comirnaty with Pfizer, with an expanding pipeline in infectious disease vaccines. Comparable as a competing platform-based vaccine developer addressing similar viral indications.
• Merck & Co. Owner of Gardasil (HPV vaccine), one of the largest vaccines globally, with deep infectious disease vaccine portfolio. Directly comparable on the HPV indication and as a potential acquirer of novel vaccine platforms.
• Moderna: Established mRNA vaccine leader with approved COVID-19 vaccine (Spikevax) and a broad pipeline including influenza and other viral vaccines. Overlaps with Vaxart on COVID-19 and influenza indications and vaccine platform competition.
• Pfizer: Global vaccine leader with Comirnaty (COVID-19, partnered with BioNTech) and a broad infectious disease vaccine portfolio. Represents the incumbent competitor that any oral vaccine must displace or partner with.
• Sanofi: Major vaccine manufacturer (Sanofi Pasteur) with broad influenza and infectious disease portfolio. Comparable as an established vaccine incumbent competing for the same viral vaccine market opportunities.
• Novavax: Protein subunit COVID-19 vaccine developer (Nuvaxovid) with additional pipeline in influenza and other infectious diseases. Comparable as a non-mRNA vaccine platform competitor with overlapping indications.
• GSK: Global vaccines leader with established HPV, influenza, and other viral vaccines. Comparable as an incumbent across multiple of Vaxart's target indications and a potential large-pharma partner or acquirer.

Emerging players

• Altimmune: Clinical-stage biotech developing intranasal vaccines (including for COVID-19 and influenza) that target mucosal immunity. Highly comparable to Vaxart on mucosal-immunity approach and alternative delivery modality (needle-free).
• CyanVac: Privately held clinical-stage company developing an intranasal COVID-19 vaccine (CVXGA). Comparable as a small-cap developer of a needle-free, mucosal-immunity COVID-19 vaccine candidate.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biota Holdings